Design, synthesis and biological evaluation of heteroaryl diketohexenoic and diketobutanoic acids as HIV-1 integrase inhibitors endowed with antiretroviral activity
- 28 April 2005
- journal article
- review article
- Published by Elsevier in Il Farmaco
- Vol. 60 (5), 409-417
- https://doi.org/10.1016/j.farmac.2005.03.008
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- The failure of HAART to cure the HIV-1/AIDS complex. Suggestions to add integrase inhibitors as complementary virostatics, and to replace their continuous long combination applications by short sequences differing by drug rotations.Biomedicine & Pharmacotherapy, 2001
- HIV-1 integrase: the next target for AIDS therapy?Pathologie Biologie, 2001
- Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug designProceedings of the National Academy of Sciences, 1999
- Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entryNature Medicine, 1998
- Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases 1 1Edited by R. HuberJournal of Molecular Biology, 1998
- The Art of 'HAART': Researchers Probe the Potential and Limits of Aggressive HIV TreatmentsPublished by American Medical Association (AMA) ,1997
- 5 Inhibitors of HIV ProteinaseProgress in Medicinal Chemistry, 1995
- Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compoundsBiochemical Pharmacology, 1994
- Inhibitors of human immunodeficiency virus integrase.Proceedings of the National Academy of Sciences, 1993
- Retroviral DNA Integration Directed by HIV Integration Protein in VitroScience, 1990